Skip to main content Skip to main navigation menu Skip to site footer
Scientific Electronic Archives
Health Science
DOI: 10.36560/13920201073
Submitted: 2020-03-04
Published: 2020-09-01

Pharmaceutical care in the context of an Extension Project to care for patients with vaginal candidiasis with the strategy of carrying out antifungal resistance testing and community health prevention

Universidade Federal do Rio Grande do Sul (UFRGS)
##plugins.generic.jatsParser.article.authorBio##
×

M. L. Menz

Departamento de Análises, Faculdade de FArmácia, UFRGS, Farmacêutica.
Universidade Federal do Rio Grande do Sul
##plugins.generic.jatsParser.article.authorBio##
×

L. N. Calil

Departamento de Análises, Faculdade de Farmácia, UFRGS, Citologia.
Universidade Federal do Rio Grande do Sul (UFRGS)
##plugins.generic.jatsParser.article.authorBio##
×

F. M. Bittencourt

Departamento de Análises, Faculdade de FArmácia, UFRGS, Farmacêutica.
Universidade Federal do Rio Grande do Sul (UFRGS).
##plugins.generic.jatsParser.article.authorBio##
×

A. Mezzari

Departamento de Análises, Faculdade de Farmácia, UFRGS, área da Microbiologia.
vaginal candidiasis susceptibility testing resistance Candida spp. Pharmaceutical attention pharmacist.

Abstract

Vaginal candidiasis, fungal infection caused by species of Candida spp. that affects women of all ages, cultures, habits, social and economic conditions. Its frequency and epidemiology is already reported, but resistance and therapeutic failures have been recorded. Methodology: In the Laboratory of Clinical and Toxicological Analyzes of the Faculty of Pharmacy of UFRGS (LACT), cervicovaginal collections of women were performed for Candida research and determination of species, after which susceptibility tests were performed to fluconazole, itraconazole, ketoconazole and nystatin. With the results obtained complement with the Pharmaceutical Care Project. Results: C. albicans was identified in 37% and in non-albicans species, C. glabrata in 27%. C. albicans was more sensitive to antifungals than C. glabrata, which presented a minimum inhibitory concentration (MIC) higher than C. albicans. Conclusion: Antifungal resistance has increased due to the use in prophylaxis and treatments without the correct diagnosis, requiring a more careful look at these patients. Thus, it is necessary to follow up the diagnosis and treatment by the health professional, the pharmacist, who has knowledge of the drug therapy used and this is obtained by the Pharmaceutical Care acting in the Project.

References

  1. ALVES, MB., SILVA, IMO., SANTOS, CI., FRANÇA, YR., OLIVEIRA, SKR., MONTEIRO, SG., MONTEIRO, CA. Prevalência de Candida spp. em amostras de secreção vaginal e sua relação com fatores associados à vulvovaginite. Rev de Investigação Biomédica 7(1):58-68, 2015.
  2. ARAÚJO, ALA., FREITAS, O. Concepções do profissional farmacêutico sobre a assistência farmacêutica na unidade básica de saúde: dificuldades e elementos para a mudança. Rev Bras Ciênc Farm (Braz J Pharmacl Scienc) 42(1):137-146, 2006.
  3. BARBERATO, LC., SCHERER, MDA., LACOURT, RMC. O farmacêutico na atenção primária no Brasil: uma inserção em construção. Ciência e Saúde Coletiva 24(10):3717-3726, 2019.
  4. BITEW, A., ABEBAW, Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC Women's Health 18(1):94, 2018.
  5. BRANDOLT, TM., KLAFKE, GB., GONÇALVES, CV., BITENCOURT, LR., MARTINEZ, AMB., MENDES, JF., MEIRELES, MCA., XAVIER, MO. Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates. Braz J Microbiol 48:145-150, 2017.
  6. CALVO, NL., SREEKUMAR, S., SVETAZ, LA. MARÃA, CL., BRUNO, MM. DARÃO, L. Design and Characterization of Chitosan Nanoformulations for the Delivery of Antifungal Agents. International J Molecr Scienc 20(15):3686, 2019.
  7. Clinical And Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard – Third Edition. CLSI Document M27-A3. Clinical Laboratory Standards Institute, Wayne, PA, USA, 2008.
  8. Clinical And Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard – Third Edition. CLSI Document M27-S4. Clinical Laboratory Standards Institute, Wayne, PA, USA, 2012.
  9. DIADHIOU M., BA, DA., BARRY, MS., ALAVO, SC., ALAMEDA, I. GASSAMA, O. NDIAYE, GMD., NDAO, FA., GAWA, E., GAYE, DA., MOREAU, JC. Prevalence and Risk Factors of Lower Reproductive Tract Infections in Symptomatic Women in Dakar, Senegal. Infect Dis: Research and Treatment 31:12, 2019.
  10. FENG, W., YANG, J., YANG, L., LI, Q., ZHU, X., XI, Z., QIAO, Z., CEN, Z. Research of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications. Experimental and Therapeutic Medicine 15:1217-1224, 2018.
  11. FOPPA, AA., BEVILACQUA, G., PINTO, L. H., BLATT, CR. Atenção farmacêutica no contexto da estratégia de saúde da família. Braz J Pharmac Scienc 44(4):727-737, 2008.
  12. GONÇALVES, B., AZEVEDO, N.M., HENRIQUES, M., SILVA, S. Hormones modulate Candida vaginal isolates biofilm formation and decrease they susceptibility to azoles and hydrogen peroxide. Medical Mycology, 2019.
  13. GUNTHER, LS., MARTINS, HP., ABREU, AL., CONSOLARO, ME., SVIDZINSKI, TI. Prevalence of Candida albicans and non-albicans isolates from vaginal secretions: comparative evaluation of colonization, vaginal candidiasis and recurrent vaginal candidiasis in diabetic and non-diabetic women. São Paulo Medical J 132(2):116-20, 2014.
  14. HARTMANN, A., MISSIO, R., HAMMAD, MP., ALVES, IA. Incidência de Candida spp. na mucosa oral de pacientes infectados pelo Vírus da Imunodeficiência Humana (HIV) no município de Santo Ângelo-RS : relação com HIV. R Epidemiol Control Infec 6(3):125-130, 2016.
  15. JI, C., LIU, N., TU, J., LI, Z., HAN, G., LI, J., SHENG, C. Drug Repurposing of Haloperidol: Discovery of New Benzocyclane Derivatives as Potent Antifungal Agents against Cryptococcosis and Candidiasis. ACS Infec deseas, 2019.
  16. KIASAT, N., MATEHKOLAEI, AR., MAHMOUDABADI, AZ. Microsatellite Typing and Antifungal Susceptibility of Candida glabrata Strains Isolated From Patients With Candida Vaginitis. Front Microbiol 10:1678, 2019.
  17. LI, Q., LIU, J., SHAO, J., DA, W., SHI, G., WANG, T., WU, D., WANG, C. Decreasing Cell Population of Individual Candida Species Does Not Impair the Virulence of Candida albicans and Candida glabrata Mixed Biofilms. Front Microbiol 10, 2019.
  19. LI, T., LIU, Z., ZHANG, X., CHEN, X., WANG, S. Local Probiotic Lactobacillus crispatus and Lactobacillus delbrueckii Exhibit Strong Antifungal Effects Against Vulvovaginal Candidiasis in a Rat Model. Front Microbiol 10:1033, 2019.
  20. LUQUETTI, TM., SANTOS, JB. BITENCOURT, G R., CASTILHO, SR., ELIAS, SC. Pharmaceutical services in primary health care: Perception of pharmacists. Diversitates Internat J 9(3): 2017.
  22. MENEGHEL, SN. ANDRADE, DP. Conversas entre mulheres durante o exame citopatológico. Saúde e Sociedade 28(2):174-186, 2019.
  23. NGOUANA, TK; TOGHUEO, RMK., KENFACK, IF., LACHAUD, L., NANA, AK., TADJOU, L., KOUANFACK, C. BOYOM, FF. BERTOUT, S. Epidemiology and antifungal susceptibility testing of non-albicans Candida species colonizing mucosae of HIV-infected patients in Yaoundé (Cameroon). Journal de Mycologie Médicale 29:233-238, 2019.
  24. NUNES, PHC., PEREIRA, BMG., NOMINATO, JCS., ALBUQUERQUE, EM., SILVA, LFN., CASTRO, IRS., CASTILHO, SR. Intervenção farmacêutica e prevenção de eventos adversos. R Brasil Ciênc Farmac (Braz J Pharmac Scienc) 44(4):692-699, 2008.
  26. . PEREIRA, LRL., FREITAS, O. A evolução da Atenção Farmacêutica e a perspectiva para o Brasil. R Bras Ciênc Farmac (Braz J Pharmac Scienc) 44(4):601-612, 2008
  27. PEREIRA, MS. Influência da microbiota vaginal na incidência de lesões intraepiteliais cervicais HPV – induzidas. Dissertação do curso de pós graduação em Ciências Biológicas, Juiz de Fora, 2018.
  28. SARDARI A., ZARRINFAR, H., MOHAMMADI R. Detection of ERG11 point mutations in Iranian fluconazole-resistant Candida albicans isolates. Current Medical Mycology 5(1):7-14, 2019.
  29. SOUZA, LB., SOUZA, DM., SOUZA, SM., SILVA, DR., AGUILAR, NC. Importância do farmacêutico clínico no uso seguro e racional de medicamentos no âmbito hospitalar. Revista Pensar Acadêmico 16(1): 2018.
  30. TABILE, PM., LUCENA, H., CHAVES, J., FISCHBORN, J., JUCÃ, RB. Características clínicas, prevalência e diagnóstico de vulvovaginites em ambulatório do interior do Rio Grande do Sul: dados e importância do diagnóstico. J Health and Biolog Scienc 4(3):160-165, 2016.
  31. VIEIRA, FS. Possibilidades de contribuição do farmacêutico para a promoção da saúde. Ciência e Saúde Coletiva 12(1):213-220, 2007.
  32. ZHAI, Y., LIU, J., ZHOU, L., JI, T., MENG, L., GAO, Y., LIU, R., WANG, X., LI, L., LU, L., CAO, Z. Detection of Candida species in pregnant Chinese women with a molecular beacon method. J Med Microbiol 67(6):783-789, 2018.

How to Cite

Menz, M. L., Calil, L. N., Bittencourt, F. M., & Mezzari, A. (2020). Pharmaceutical care in the context of an Extension Project to care for patients with vaginal candidiasis with the strategy of carrying out antifungal resistance testing and community health prevention. Scientific Electronic Archives, 13(9), 91–98. https://doi.org/10.36560/13920201073